CDK6 and acute myeloid leukemia: Our results describe a new mechanism by which bort suppresses self‐renewal of LSC by NF‐ĸB‐dependent inhibition of CDK6 in MLL‐arranged leukaemia, indicating that bort might be a potential drug for AML patients with MLL rearrangements.